Gore gains CE mark for new endovascular aneurysm treatment device; Scientists blend MRI and ultrasound for gentler breast biopsies;

@FierceMedDev: ICYMI: OrthoSensor links with Zimmer to sell knee replacement-balancing tech. Story | Follow @FierceMedDev

@MarkHFierce: Foundation Medicine's first quarterly earnings as a public company reflect impressive growth. Article | Follow @MarkHFierce

@MichaelGFierce: From FierceDrugDelivery this week: Novo Nordisk wins FDA approval for two automated-dose insulin pens. More | Follow @MichaelGFierce

> Some hospital customers are making sure in their contracts with device companies that costs relating to the 2.3% device tax aren't passed on to them. Story (sub. req)

> W.L. Gore won a CE mark for a device designed for the endovascular treatment of iliac or aortoiliac aneurysms. Item

> Italy's Sorin Group disclosed the first European implant of its Mitroflow Valsalva Conduit, which it bills as the only aortic root surgery system of its kind with bovine pericardium valve. It recently won a CE mark. Item

> Scientists have developed a cheaper and gentler way to conduct breast biopsies for breast cancer patients that involves combining MRI and ultrasound imaging. Story

> Colorado's EndoShape won 510(k) clearance for its new vascular plug, and it plans to launch it commercially in early 2014. Item

Biotech News

@FierceBiotech: Teva fills CFO position as Desheh steps up to CEO, plus more of this week's career moves in biopharma. News | Follow @FierceBiotech

@JohnCFierce: FDA bottom line: unless there's a fantastic benefit, don't approve Lemtrada. Sanofi shares slip. | Follow @JohnCFierce

@DamianFierce: Updated Ariad job-cut story: EMA committee says Iclusig OK for now; stronger label on the way. More | Follow @DamianFierce

@EmilyMFierce: ICYMI: Report proposes revamping Alzheimer's R&D. Story | Follow @EmilyMFierce

> J&J innovation team sets up international collaboration to discover Alzheimer's drugs. Story

> Bristol-Myers axing up to 75 R&D staffers, halts discovery work in three fields. Article

> Sangart goes MIA after burning through $260M-plus on R&D. News

> FDA casts 'fatal' doubts on Sanofi's long-stalled MS drug Lemtrada. More

Pharma News

@FiercePharma: Best-read story this morning: Top 10 Drug Patent Losses for 2014. More | Follow @FiercePharma

@CarlyHFierce:  EU watchdogs demand info on AstraZeneca's disputed Brilinta trial. More | Follow @CarlyHFierce

> Gastro specialist Salix nabs Santarus and new colitis drug in $2.6B deal. Story

> After Bristol-Myers R&D cuts, will AstraZeneca amp up its share of diabetes JV? News

> EU watchdogs demand info on AstraZeneca's disputed Brilinta trial. Article

> Eisai bets another $60M on Arena's Belviq with worldwide marketing deal. Story

Suggested Articles

In an SEC filing, Baxter International disclosed that it may have overstated its income over multiple years, inflating it by about $276 million.

The FDA has given Grail a green light to conduct the interventional study, and it has begun enrolling participants through the company’s R&D partners.

Coronavirus may not require a front-line battle yet in certain places, but it’s still taxing public health officials preparing for a potential crisis.